Disclosed positions

Estimated from their latest filings — positions may have changed since

$1.65M

combined est. value

Stock	Shares	Price	Value	Weight	As of
SIBNSI-BONE, Inc.	43,772	$16.89	$739.3K	45%	2026-06-04
OMDAOmada Health, Inc.	26,519	$22.98	$609.4K	37%	2026-07-05
NVCRNovoCure Ltd	16,806	$17.83	$299.7K	18%	2025-06-04

SIBN

SI-BONE, Inc.

$739.3K

43,772 sh

OMDA

Omada Health, Inc.

$609.4K

26,519 sh

NVCR

NovoCure Ltd

$299.7K

16,806 sh

All filings on record

Every Form 4 transaction we track for this filer

all 11buys 0sells 1

Stock	Transaction	Date	~6mo later
OMDAOmada Health, Inc.	Grant — · 1,299 sh	2026-07-05	—
SIBNSI-BONE, Inc.	Grant — · 10,957 sh	2026-06-04	—
OMDAOmada Health, Inc.	Grant — · 1,601 sh	2026-01-05	—
OMDAOmada Health, Inc.	Grant — · 1,126 sh	2025-10-05	—
HLVXHilleVax, Inc.	Other — · 59,224 sh	2025-09-17	—
OMDAOmada Health, Inc.	Grant — · 376 sh	2025-07-05	—
HLVXHilleVax, Inc.	Grant — · 17,199 sh	2025-06-23	—
OMDAOmada Health, Inc.	Grant — · 9,736 sh	2025-06-05	—
SIBNSI-BONE, Inc.	Grant — · 8,675 sh	2025-06-05	—
NVCRNovoCure Ltd	Grant — · 11,215 sh	2025-06-04	—
NVCRNovoCure Ltd	Sell $17.2K · 999 sh	2025-06-03	—

OMDAGrant

2026-07-05 · Omada Health, Inc.

1,299

—

SIBNGrant

2026-06-04 · SI-BONE, Inc.

10,957

—

OMDAGrant

2026-01-05 · Omada Health, Inc.

1,601

—

OMDAGrant

2025-10-05 · Omada Health, Inc.

1,126

—

HLVXOther

2025-09-17 · HilleVax, Inc.

59,224

—

OMDAGrant

2025-07-05 · Omada Health, Inc.

376

—

HLVXGrant

2025-06-23 · HilleVax, Inc.

17,199

—

OMDAGrant

2025-06-05 · Omada Health, Inc.

9,736

—

SIBNGrant

2025-06-05 · SI-BONE, Inc.

8,675

—

NVCRGrant

2025-06-04 · NovoCure Ltd

11,215

—

NVCRSell

2025-06-03 · NovoCure Ltd

$17.2K

—

Outcomes measure each disclosed buy against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.